The Europe wound care market size was anticipated at USD 5.8 billion in 2023 and is expected to grow at a CAGR of 3.8% from 2024 to 2030. The growing prevalence of chronic diseases across the globe is one of the key factors fueling market growth. In addition, changing lifestyles, unhealthy eating habits, increasing consumption of alcohol, and rising new cases of non-communicable diseases (NCDs), such as cancer, diabetes, chronic respiratory disease, heart disease, and antimicrobial resistance, are supporting industry growth. Europe wound care market held a 26.2% share of the global wound care market revenue in 2023.
High disposable income levels, well-established & technologically advanced healthcare infrastructure, availability of skilled professionals, positive reimbursement coverages, rising cases of surgical site infections (SSIs) & chronic wounds, and increasing geriatric population in the region are also fueling market growth. Encouraging environment for innovative startups, innovation-backed new product launches, collaborations, mergers & acquisition strategies adopted by key companies for expansion and technology enhancements, partnerships, alliances & agreements for new product developments, and growing emphasis on R&D are other key factors expected to boost market growth.
The advanced wound dressing segment dominated the market and held the largest revenue share of 34.9% in 2023. These products are commonly used in the treatment of chronic and non-healing wounds. Some of the advanced wound dressing products are infused with antimicrobial agents, such as silver or honey, which can act as a catalyst in initiating rapid wound healing and work on preventing further infections. The limitations associated with traditional wound healing products and growing cases of chronic diseases, such as diabetes, are expected to support the segment's growth.
The surgical wound care segment is expected to register a CAGR of 4.0% from 2024 to 2030. This is primarily due to the growing prevalence of SSIs. In addition, a rising number of major surgeries performed yearly is expected to fuel segment growth. For instance, according to NCBI, around 310 million significant procedures are performed annually worldwide, of which 20 million are performed in Europe.
The chronic wounds segment dominated the market and accounted for a revenue share of 60.0% in 2023. One of the key factors driving the segment growth is the rising cases of chronic wounds in diabetic patients, such as foot ulcers. Increasing new cases of diabetes are adding to the situation. In addition, the prevalence of other chronic wounds, such as arterial, postsurgical, pressure, and venous stasis ulcers, is expected to fuel segment growth.
The acute wounds segment is expected to experience a CAGR of 3.9% from 2024 to 2030. This can be attributed to growing trauma cases in the region. These wounds include surgical & traumatic wounds and burn wounds. Treatment alternatives for acute wound care are advanced dressings, biologics, and traditional wound care products.
The hospitals segment held the highest revenue share of 39.0% in 2023. Hospitals are equipped with resources and investments to adopt advanced wound care technologies and innovation-backed equipment. This, in turn, leads to optimized patient outcomes. Hospitals in Europe offer specialized dressings, deliver innovative therapies, and utilize advanced devices in wound care treatments.
The home healthcare segment is expected to experience a significant CAGR of 5.2% from 2024 to 2030. The anticipated growth can be attributed to various factors, such as a large pool of geriatric population, growing adoption of advanced wound care techniques in home healthcare, and rising incidences of diabetic foot ulcers, venous leg ulcers, & pressure ulcers.
The prescribed mode of purchase segment dominated the industry and accounted for 62.7% share of the overall revenue in 2023. Wound care management is commonly monitored according to directions and instructions provided by experts, physicians, and surgeons. According to Public Health England, over 26% of the total adult population in the UK prefers prescription medications.
The segment is projected to expand further at a lucrative CAGR from 2024 to 2030. This is mainly due to the inclination to purchase prescribed wound care products owing to Medicare benefits that can only be available when a licensed healthcare practitioner prescribes the products.
The institutional sales segment held the largest revenue share of 81.4% in 2023. The institutional distribution mainly comprises clinics, hospitals, dedicated wound care clinics, and other healthcare settings, such as long-term care facilities, diagnostic laboratories, nursing homes, and birth centers. The key companies engage in long-term contracts with these healthcare facilities to enhance their market penetration and sales every year.
The retail sales segment is expected to experience a CAGR of 4.2% from 2024 to 2030. This is primarily due to the easy accessibility to retail distribution points, such as pharmacy stores and e-commerce websites. Usually, customers without prescribed wound care treatment buy products from retail pharmacy stores for regular or emergency treatments. Online shopping for wound care products is preferred by customers needing quick home deliveries and easy accessibility.
The UK wound care market dominated the regional market and accounted for a share of 17.1% in 2023. This can be attributed to factors including the rising number of diabetic patients suffering from foot injuries & other chronic wounds, the presence of several small- & mid-sized companies, constant new product launches, and expansion strategies adopted by key companies in the country in terms of manufacturing and distribution.
The wound care market in Spain is expected to register a CAGR of 4.2% from 2024 to 2030. This is primarily due to the growing expenditure on healthcare, increasing geriatric population, rising disposable income levels, and high prevalence of chronic diseases in the country. According to NCBI, more than 90% of the deaths in the country are caused by chronic diseases.
Some of the key and emerging companies in the market include Smith & Nephew PLC, Mölnlycke Health Care AB, ConvaTec Group PLC, Coloplast Corp., and Medtronic. Market players undertake several strategies to establish a competitive advantage over other players, such as collaborations, expansions, post-purchase assistance, innovation, and product differentiations.
Medtronic is a medical devices company known for delivering solutions equipped with groundbreaking technologies for the most intricate and puzzling situations. The company operates in four key segments, namely, cardiac & vascular, minimally invasive therapies, diabetes, and restorative therapies. It has a global geographical reach and operates in nearly 150 countries. Some of its key customers include surgery centers, long-term care facilities, and home healthcare providers
Smith & Nephew manufactures and distributes medical devices and services. The company provides sports medicine & ENT, orthopedics, and advanced wound care management services through distribution centers. The company’s products include instruments and implants, devices required for minimally invasive surgery, and products for the treatment of acute and chronic wounds, such as diabetic ulcers, postoperative wounds, and leg burns
Report Attribute |
Details |
Market size value in 2023 |
USD 5.8 billion |
Revenue forecast in 2030 |
USD 7.6 billion |
Growth rate |
CAGR of 3.8% from 2024 to 2030 |
Base year for estimation |
2023 |
Historical data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, application, end-use, mode of purchase, distribution channel, country |
Country scope |
UK; Germany; France; Spain; Italy; Sweden; Norway; Denmark |
Key companies profiled |
Smith+Nephew; Mölnlycke Health Care AB; Convatec Group PLC; Coloplast Corp; Medtronic; PAUL HARTMANN AG; INTEGRA LIFESCIENCES; B. Braun SE |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the Europe wound care market report based on product, application, end-use, mode of purchase, distribution channel, and country:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Advanced Wound Dressing
Traditional Wound Care
Surgical Wound Care
Wound Therapy Devices
Application Outlook (Revenue, USD Million, 2018 - 2030)
Chronic Wounds
Acute Wounds
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Specialty Clinics
Home Healthcare
Physician Office
Nursing Homes
Others
Mode of Purchase Outlook (Revenue, USD Million, 2018 - 2030)
Prescribed
Non-prescribed (OTC)
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Institutional Sales
Retail Sales
Country Outlook (Revenue, USD Million, 2018 - 2030)
Germany
Italy
Spain
The Netherlands
Russia
Sweden
UK
b. The Europe wound care market size was valued at USD 5.8 billion in 2023.
b. The Europe wound care market is expected to grow at a CAGR of 3.8% from 2024 to 2030 to reach USD 7.6 billion by 2030.
b. The advanced wound dressing segment dominated the market and held the largest revenue share of 34.9% in 2023. These products are commonly used in the treatment of chronic and non-healing wounds. Some of the advanced wound dressing products are infused with antimicrobial agents such as silver or honey, which can act as a catalyst in initiating rapid wound healing and work on preventing further infections.
b. Some of the key and emerging companies in the Europe Wound Care Market include Smith & Nephew PLC, Mölnlycke Health Care AB, ConvaTec Group PLC, Coloplast Corp., Medtronic and others.
b. The growing prevalence of chronic diseases across the globe is one of the key factors fueling growth for this market. In addition, aspects such as changing and unhealthy lifestyles, unceasing consumption of alcohol, and rising new cases of non-communicable diseases (NCDs) such as cancer, diabetes, chronic respiratory disease, heart disease, and antimicrobial resistance are also assisting this market to grow at a lucrative rate.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."